Cases
Cases
Updated Oct 21, 9:57 PM ET
Petition filed
Plan confirmed
Vyera is in post-effectiveness liquidation and claims administration under its joint Subchapter V plan, whose effectiveness was reported in the October 11, 2023 notice Dkt. 319. The trustee’s remaining work includes pursuing litigation recoveries and reconciling claims, with the claims-objection deadline extended to May 10, 2027 by the May 11, 2026 order Dkt. 451.
Search available documents for this case. Full docket access requires Pro.
Open case researchVyera Pharmaceuticals: Daraprim Legacy Ends in Liquidation ·
Case facts and filing dates come from court records.
Updated Oct 21, 9:57 PM ET
Petition filed
Plan confirmed
Vyera is in post-effectiveness liquidation and claims administration under its joint Subchapter V plan, whose effectiveness was reported in the October 11, 2023 notice Dkt. 319. The trustee’s remaining work includes pursuing litigation recoveries and reconciling claims, with the claims-objection deadline extended to May 10, 2027 by the May 11, 2026 order Dkt. 451.
Search available documents for this case. Full docket access requires Pro.
Open case researchVyera Pharmaceuticals: Daraprim Legacy Ends in Liquidation ·
Case facts and filing dates come from court records.